Sector: health
Conviction from: NASDAQ
52-week range: 62.5093.42
BridgeBio Pharma develops medicines for genetic diseases and cancers, advancing a pipeline of targeted therapies across multiple rare-disease programs.
3 tracked filer(s) hold this · 0 opened, 1 added, 2 trimmed in 30-SEP-2026
Aggregate 13FScore 64 — mean of 3 scored holder(s) · buyers (new/add) avg 55. Higher = the smart money in this name has the better track record.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-04-02 | SCHEDULE 13D/A | VIKING GLOBAL INVESTORS LP | 6.1% | Med | filing |
| 2026-02-17 | SCHEDULE 13D/A | VIKING GLOBAL INVESTORS LP | 6.8% | Med | filing |
8 disclosed trade(s) by 1 filer(s).
| Trade date | Who | Type | Amount | |
|---|
| 2026-11-02 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-10-27 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-09-29 | Gilbert Cisneros CA31 | SELL | $1,001 - $15,000 | PTR |
| 2026-05-11 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-04-29 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-03-19 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-03-18 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-03-03 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
1 disclosed trade(s) by 1 filer(s).